Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer
Autor: | Fatma Sen, Erkan Topuz, Alper Toker, Esra Sağlam, Pinar Saip, Ethem Nezih Oral, Barkin Sakallioglu, Ahmet Kizir, Sukru Dilege, Adnan Aydiner |
---|---|
Rok vydání: | 2011 |
Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Docetaxel Toxicology Disease-Free Survival Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Pharmacology (medical) neoplasms Aged Neoplasm Staging Pharmacology Cisplatin business.industry Consolidation Chemotherapy Chemoradiotherapy Middle Aged Combined Modality Therapy Surgery Stage III Non-Small Cell Lung Cancer Radiation therapy Concomitant Locally advanced disease Female Taxoids Non small cell business medicine.drug |
Zdroj: | Cancer Chemotherapy and Pharmacology. 68:1497-1505 |
ISSN: | 1432-0843 0344-5704 |
Popis: | The aim of this study was to evaluate efficacy and feasibility of a combination of weekly docetaxel and cisplatin administered concomitantly with radiotherapy followed by surgery in addition to consolidation chemotherapy with docetaxel and cisplatin administered every 3 weeks in stage III non-small cell lung cancer (NSCLC).A total of 31 histologically proven, locally advanced (stage IIIA-N2 = 9, stage IIIB-T4N0-2 = 22) NSCLC patients were investigated. After administration of 4-6 cycles of weekly docetaxel (20 mg/m(2)) and weekly cisplatin (20 mg/m(2)) concurrently with radiotherapy, patients underwent operation if their disease was appropriately downstaged. Combination chemotherapy with docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) every 3 weeks was administered as a consolidation regimen. The treatment response, toxicity, time to progression (TTP) and overall survival (OS) were evaluated.After concomitant chemoradiotherapy, complete response and partial response occurred in 16.1 and 67.7% of patients, respectively. Thirteen percentage of patients progressed on treatment, and 3.2% had stable disease. Grade 3-4 hematologic and skin toxicities did not occur, whereas 17.9% of them experienced grade 3-4 oesophageal toxicity. Grade 3 pulmonary toxicity and grade 3-4 emesis developed in 9.7 and 6.4% of patients, respectively. Thirteen responsive patients (41.9%) underwent surgery. The toxicity of consolidation chemotherapy was tolerable. Median OS and TTP were 22 ± 5 (range 13-31) and 12 ± 3 (range 7-17) months, respectively. Median follow-up was 22 (range 2-57) months.Weekly administration of docetaxel and cisplatin concurrently with radiotherapy followed by consolidation chemotherapy is an effective treatment with acceptable toxicity for patients with locally advanced NSCLC especially in combination with surgery. |
Databáze: | OpenAIRE |
Externí odkaz: |